Longitudinal assessment of antipneumococcal susceptibility in the United States. - Wikidata - wikimedia - TriplyDB

Longitudinal assessment of antipneumococcal susceptibility in the United States.

Longitudinal assessment of antipneumococcal susceptibility in the United States.

http://www.wikidata.org/entity/Q34110932

about

National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Predicting the clinical efficacy of generic formulations of ceftriaxone.Reinterpretation of susceptibility data using current NCCLS breakpoint criteria.Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.

P2860

Q24682283-BC120D93-49FC-4789-A455-7931AE2421B5 Q33770218-28AE472A-6ED3-4446-B762-A09AA307540A Q34230118-404CB56B-BE66-494A-8B56-B56E16A56225 Q34502866-1AFEDE74-23AC-4F98-B597-59B1D6D9BD87 Q36337074-0A17BCB2-C85A-494D-96C9-BE3150F5BE6B Q36728602-C71F52DE-D6F4-441C-B7CE-735C25A9461C Q37719126-DAD61FCA-1104-4F89-A085-3555292657A4 Q37733449-0D61DC09-CEEC-4B33-B430-470DCB0AC045 Q40369183-7FF66525-9489-4CC6-BC45-D0F0E12AFB4F Q42858208-07811A2B-622F-42F0-959E-D3AE64BE919C Q44959691-2C2AC83A-E73F-44A7-86D4-9A4235834AFC

P2860

Longitudinal assessment of antipneumococcal susceptibility in the United States.

http://www.wikidata.org/entity/Q34110932

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@ast

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@en

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@nl

type

label

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@ast

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@en

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@nl

prefLabel

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@ast

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@en

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@nl

P1433

Q34110932-70EDBBE9-4E50-44F4-ADE6-7648382E9B6D

P1476

Q34110932-808F5351-C512-4C03-BB5B-8601986B3E17

P2093

Q34110932-504C2FD2-B079-486A-8A7B-0236157222DD

Q34110932-5689FB4E-9FEF-4E52-B603-FDD5A5BB0ADD

Q34110932-660DFEFB-28E7-4748-994A-9D5BCC1E45B0

Q34110932-9838DDBB-703F-4972-A00D-7B867DA9BFF0

Q34110932-C6425C6A-1240-484D-B0EA-440E299180C5

Q34110932-E845D90F-6835-4858-82A1-E9A244342594

Q34110932-FF25A279-27AD-40F1-B64F-3D8EB7539B1F

P2860

Q34110932-0A07F3BA-536F-41BA-9CEE-74ED6FC9D287

Q34110932-289B7F5D-75B2-4BD4-86FB-AE33C917FAA8

Q34110932-3A34A345-F9AA-4F9E-99EF-D29AEAC817FD

Q34110932-4D27ECB2-F8B1-4136-A7A2-87D0CDEE16B6

Q34110932-51E41FA4-3802-44F5-B89F-BFAEFE790763

Q34110932-588536E5-8BD2-48D9-BB2D-171E1D2645DB

Q34110932-5E9A8CED-C476-4944-AD20-A2D634DDCF69

Q34110932-60D6243F-A64A-4462-8063-E5AA671310EA

Q34110932-8473FC62-6812-4399-95BA-6394FBC35101

Q34110932-879D7D95-7E98-4491-95D2-76D125B32CAA

P304

Q34110932-6CC2DE85-A9C0-483E-BC36-0F3C09955E3F

P31

Q34110932-B8F2637E-3EF8-45C5-9D1B-5BA227087C4F

P356

Q34110932-EABD0EA0-0AD1-44D1-9D97-E83C48842EC5

P407

Q34110932-064F1170-87EE-44FF-9B4B-4BD02BB9BD65

P433

Q34110932-4197E21F-0144-482A-AE8B-AABAFA66A103

P478

Q34110932-1CD8C977-7E63-4086-B907-FC4A73684A48

P577

Q34110932-0AA778B8-698E-49FE-878B-6A4C9EC6A01D

P698

Q34110932-300E3CA8-BFD3-4A84-B915-A38F64D3BC66

P921

Q34110932-18F352FA-62EE-4FAA-84BF-D616596FD3A5

P932

Q34110932-982B7AAB-EBC9-49EF-94D0-CFF31F506B45

P356

AAC.46.8.2651-2655.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Longitudinal assessment of antipneumococcal susceptibility in the United States.

@en

P2093

Clyde Thornsberry

http://www.w3.org/2001/XMLSchema#string

Daniel F Sahm

http://www.w3.org/2001/XMLSchema#string

Elena Karginova

http://www.w3.org/2001/XMLSchema#string

Ian A Critchley

http://www.w3.org/2001/XMLSchema#string

James A Karlowsky

http://www.w3.org/2001/XMLSchema#string

Mark E Jones

http://www.w3.org/2001/XMLSchema#string

Renée Blosser-Middleton

http://www.w3.org/2001/XMLSchema#string

P2860

Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.

Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.

Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae.

P304

2651-2655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.8.2651-2655.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12121949

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq

P932

127351

http://www.w3.org/2001/XMLSchema#string